Female Hormone Restoration References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33.
  2. Grady D, Herrington D, Bittner V, et al. HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002 Jul 3;288(1):49-57.
  3. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):58–66.
  4. Azoulay C. [Menopause in 2004: "hormone replacement therapy" is not what it used to be anymore]. Rev Med Interne. 2004 Nov;25(11):806–815.
  5. Moskowitz D. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks. Altern Med Rev. 2006 Sep;11(3):208-23.
  6. Ragaz J, et al. Hormone replacement therapy utilizing estrogen alone provides a protective effect in reducing breast cancer risk. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, Dec. 8-12, 2010.
  7. Roumie CL, Grogan EL, Falbe W, et al. A three-part intervention to change the use of hormone replacement therapy in response to new evidence. Ann Intern Med. 2004 Jul 20;141(2):118-25.
  8. Schonberg MA, Davis RB, et al. After the Women's Health Initiative: decision making and trust of women taking hormone therapy. Womens Health Issues. 2005;15(4): 187-195.
  9. Sharma S. Hormone Replacement Therapy in menopause: current concerns and considerations. Kathmandu Univ Med J (KUMJ). 2003 Oct-Dec;1(4):288-93.
  10. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies. Endocr Rev. 2006 Oct;27(6):575-605.
  11. Chlebowski RT, Anderson GL, Gass M, et al. WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010 Oct 20;304(15):1684-92.
  12. Holtorf K. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? Postgrad Med. 2009;121(1): 73-85.
  13. Wren BG. The benefits of oestrogen following menopause: why hormone replacement therapy should be offered to postmenopausal women. Med J Aust. 2009 Mar 16;190(6):321-5.
  14. Lenfant F, Trémollières F, Gourdy P, Arnal JF. Timing of the vascular actions of estrogens in experimental and human studies: Why protective early, and not when delayed? Maturitas. 2010 Dec 15. [Epub ahead of print].
  15. Lee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM. The oncogenic potential of endometrial polyps: a systematic review and meta-analysis. Obstet Gynecol. 2010 Nov;116(5):1197-205.
  16. Sitruk-Ware R. New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation. Climacteric. 2007;10(5): 358-370.
  17. Kubista E. Diagnosis and therapy of fibrocystic breast disease. Zentralbl Gynakol. 1990;112(17):1091–1096.
  18. Bentrem D, Fox JE, Pearce ST, et al. Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Res. 2003;63(21):7490–7496.
  19. Bradlow HL, Davis DL, Lin G, et al. Effects of pesticides on the ratio of 16 alpha/2-hydroxyestrone: a biologic marker of breast cancer risk. Environ Health Perspect. 1995;103(Suppl 7):147–150.
  20. Papaconstantinou AD, Umbreit TH, Fisher BR, et al. Bisphenol A-induced increase in uterine weight and alterations in uterine morphology in ovariectomized B6C3F1 mice: role of the estrogen receptor. Toxicol Sci. 2000;56(2):332–339.
  21. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev. 1997 Feb;18(1):71-106.
  22. Bhavnani BR. Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Biochem Mol Biol. 2003; 85(2–5):473–482.
  23. Wright JV, Schliesman B, Robinson L. Comparative measurements of serum estriol, estradiol, and estrone in non-pregnant, premenopausal women; a preliminary investigation. Altern Med Rev. 1999 Aug;4(4):266-70.
  24. Lee JR, Hopkins V. What Your Doctor May Not Tell You About Menopause: The Breakthrough Book on Natural Progesterone. New York: Warner Books, 1996.
  25. Tapiero H, Ba GN, et al. Estrogens and environmental estrogens. Biomed Pharmacother. 2002 Feb;56(1):36–44.
  26. Simone CB. Cancer and Nutrition. Lawrenceville, NJ: Princeton Institute; 2005.
  27. Haber D. Roads leading to breast cancer. N Engl J Med. 2000 Nov 23;343(21):1566-8.
  28. Taioli E, Im A, Xu X, et al. Comparison of estrogens and estrogen metabolites in human breast tissue and urine. Reprod Biol Endocrinol. 2010 Aug 2;8:93.
  29. Head KA. Estriol: safety and efficacy. Altern Med Rev. 1998;3(2):101–113.
  30. Kano H, Hayashi T, et al. Estriol retards and stabilizes atherosclerosis through an NO-mediated system. Life Sci. 2002;71(1): 31-42.
  31. Bradlow HL, Telang NT, et al. 2-hydroexysterone: the good estrogen. J Endocrinol. 1996:150:259-265.
  32. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000;11(6):635–640.
  33. Wong GY, Bradlow L, Sepkovic D, et al. Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl. 1997;28-29:111-6.
  34. Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF. Pilot study: effect of 3,3’-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 2004;50(2):161-7.
  35. Paruthiyil S, Parmar H, Kerekatte V, et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004 Jan 1;64(1):423-8.
  36. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science. 1997 Sep 5;277(5331):1508-10.
  37. Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, et al. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res. 2000;55:163-93; discussion 194-5.
  38. Nilsson S, Mäkelä S, Treuter E, Tujague M. Mechanisms of estrogen action. Physiol Rev. 2001 Oct;81(4):1535-65.
  39. Wang D, Hu L, Zhang G, Zhang L, Chen C. G protein-coupled receptor 30 in tumor development. Endocrine. 2010 Aug;38(1):29-37.
  40. Helguero LA, Faulds MH, Gustafsson JA, Haldosén LA. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene. 2005 Oct 6;24(44):6605-16.
  41. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004 Sep;11(3):537-51.
  42. Isaksson E, Wang H, Sahlin L, von Schoultz B, Masironi B, von Schoultz E, Cline JM. Expression of estrogen receptors (alpha, beta) and insulin-like growth factor-I in breast tissue from surgically postmenopausal cynomolgus macaques after long-term treatment with HRT and tamoxifen. Breast. 2002 Aug;11(4):295-300.
  43. Weatherman RV, Clegg NJ, Scanlan TS. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Chem Biol. 2001 May;8(5):427-36.
  44. Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology. 2006 Sep;147(9):4132-50.
  45. Rich RL, Hoth LR, Geoghegan KF, Brown TA, LeMotte PK, Simons SP, Hensley P, Myszka DG. Kinetic analysis of estrogen receptor/ligand interactions. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8562-7.
  46. Lappano R, Rosano C, De Marco P. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol. 2010 May 14;320(1-2):162-70.
  47. Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat. 2010 Aug;123(1):87-96.
  48. Melamen M, Castano E, Notides AC, et al. Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol. 1997 Nov;11(12):1868-78.
  49. Centers for Disease Control and Prevention (CDC). Women and Heart Disease Fact Sheet.  http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_women_heart.htm. Last updated 10/18/12.
  50. Cushman M. Hormone therapies and vascular outcomes: who is at risk? J Thromb Thrombolysis. 2003;16(1–2):87–90.
  51. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab. 2003;88(6):2470–2478.
  52. Dijsselbloem N, Vanden BW, De NA., et al. Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. Biochem Pharmacol. 2004;68(6):1171–1185.
  53. Arnal JF, Laurell H, et al. Estrogen receptor actions on vascular biology and inflammation: implications in vascular pathophysiology. Climacteric. 2009;12 Suppl 1: 12-17.
  54. Kuo BT, Choubey R, et al. Reduced estrogen in menopause may predispose women to takotsubo cardiomyopathy. Gend Med. 2010;7(1): 71-77.
  55. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest. 2006 May;116(5):1186-94.
  56. Notelovitz M. Androgen effects on bone and muscle. Fertil Steril. 2002;77(Suppl 4):S34–S41.
  57. Amtul Z, Wang L, Westaway D, et al. Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer’s disease. Neuroscience. 2010 Aug;169(2):781-6.
  58. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology. 2008 Jan 15;70(3):200-9.
  59. Liang K, Yang L, et al. Estrogen stimulates degradation of beta-amyloid peptide by up-regulating neprilysin. J Biol Chem. 2010;285(2): 935-942.
  60. Vallée M, Mayo W, Le Moal M. Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res Brain Res Rev. 2001 Nov;37(1-3):301-12.
  61. Yao Z-X, Brown RC, Teper G, et al. 22R-Hydroxycholesterol protects neuronal cells from β-amyloid-induced cytotoxicity by binding to β-amyloid peptide. J Neurochemistry. 2002 Dec;83(5):1110-19.
  62. Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci. 1998 Nov-Dec;28(6):360-9.
  63. Hayden RE, Pratt G, et al. Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2. Leukemia. 2009;23(2): 292-304.
  64. Hilton HN, Kalyuga M, et al. The antiproliferative effects of progestins in T47D breast cancer cells are tempered by progestin induction of the ETS transcription factor Elf5. Mol Endocrinol. 2010;24(7): 1380-1392.
  65. Cowan LD, Gordis L, Tonascia JA, et al. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol. 1981;114(2):209–217.
  66. Campagnoli C, Clavel-Chapelon F, et al. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005 Jul;96(2):95–108.
  67. Stein DG. The case for progesterone. Ann NY Acad Sci. 2005 Jun;1053;152–169.
  68. Takahashi K, Okada M, et al. Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod. 2000;15(5): 1028-1036.
  69. Hayashi T, Ito I, et al. Estriol (E3) replacement improves endothelial function and bone mineral density in very elderly women. J Gerontol A Biol Sci Med Sci. 2000;55(4): B183-190; discussion B191-183.
  70. Itoi H, Minakami H, et al. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early menopausal women. Maturitas. 2000;36(3): 217-222.
  71. Yamanaka Y, Matsuo H, et al. Effects of combined estriol/pravastatin therapy on intima-media thickness of common carotid artery in hyperlipidemic postmenopausal women. Gynecol Obstet Invest. 2005;59(2): 67-69.
  72. Minaguchi H, Uemura T, et al. Effect of estriol on bone loss in postmenopausal Japanese women: a multicenter prospective open study. J Obstet Gynaecol Res. 1996;22(3): 259-265.
  73. Nishibe A, Morimoto S, et al. Effect of estriol and bone mineral density of lumbar vertebrae in elderly and postmenopausal women. Nippon Ronen Igakkai Zasshi. 1996;33(5): 353-359.
  74. Nozaki M, Hashimoto K, et al. Usefulness of estriol for the treatment of bone loss in postmenopausal women. Nippon Sanka Fujinka Gakkai Zasshi. 1996;48(2): 83-88.
  75. Dessole S, Rubattu G, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause. 2004;11(1): 49-56.
  76. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11): 753-756.
  77. Kobata SA, Girao MJ, et al. Estrogen therapy influence on periurethral vessels in postmenopausal incontinent women using Dopplervelocimetry analysis. Maturitas. 2008;61(3): 243-247.
  78. Davidov MI, Petruniaev AI, et al. [Treatment of chronic cystitis in postmenopausal women]. Urologiia. 2009;(4): 14-19.
  79. Ishiko O, Hirai K, et al. Hormone replacement therapy plus pelvic floor muscle exercise for postmenopausal stress incontinence. A randomized, controlled trial. J Reprod Med. 2001;46(3): 213-220.
  80. Koloszar S, Kovacs, L. Treatment of climacteric urogenital disorders with an estriol-containing ointment. Orv Hetil. 1995;136(7): 343-345.
  81. Chollet JA, Carter G, et al. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis. Menopause. 2009;16(5): 978-983.
  82. Ozyazgan I, Liman N, et al. The effects of topical estriol and vehicle cream on the mechanical and histological properties of normal rat skin. Med Sci Monit. 2005;11(11): BR405-411.
  83. Tzingounis VA, Aksu MF, et al. Estriol in the management of the menopause. JAMA. 1978;239(16): 1638-1641.
  84. Lauritzen C. Results of a 5 years prospective study of estriol succinate treatment in patients with climacteric complaints. Horm Metab Res. 1987;19(11): 579-584.
  85. Rosano GM, Webb CM, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000;36(7): 2154-2159.
  86. Bernstein P, Pohost G. Progesterone, progestins, and the heart. Rev Cardiovasc Med. 2010 Summer;11(3):e141-9.
  87. Ottosson UB, Johansson BG, et al. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol. 1985;151(6): 746-750.
  88. Jensen J, Riis BJ, et al. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol. 1987;156(1): 66-71.
  89. Hargrove JT, Maxson WS, et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol. 1989;73(4): 606-612.
  90. Montplaisir J, Lorrain J, et al. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause. 2001;8(1): 10-16.
  91. Ryan N, Rosner A. Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women. Clin Ther. 2001;23(7): 1099-1115.
  92. Lindenfeld EA, Langer RD. Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstet Gynecol. 2002;100(5 Pt 1): 853-863.
  93. Fitzpatrick LA, Pace C, et al. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med. 2000;9(4): 381-387.
  94. Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol. 2009 Jan;30(1):65-91.
  95. Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog Brain Res. 2010;182:97-148.
  96. Genazzani AR, Pluchino N. DHEA therapy in postmenopausal women: the need to move forward beyond the lack of evidence. Climacteric. 2010 Aug;13(4):314-6.
  97. Morrison MF, Redei E, TenHave T, et al. Dehydroepiandrosterone sulfate and psychiatric measures in a frail, elderly residential care population. Biol Psychiatry. 2000 Jan 15;47(2):144-50.
  98. Kenny AM, Boxer RS, et al: Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women. J Am Geriatr Soc.2010 Sep;58(9):1707-14.
  99. Weiss EP, Shah K, Fontana L, et al. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr. 2009 May;89(5):1459-67.
  100. Ritsner MS, Gibel A, Shleifer T, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry. 2010 Oct;71(10):1351-62.
  101. Casson PR, Faquin LC, Stentz FB, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril. 1995;63(5):1027–1031.
  102. Schneider HP. Androgens and antiandrogens. Ann NY Acad Sci. 2003;997:292-306.
  103. Simon JA. Safety of estrogen/androgen regimens. J Reprod Med. 2001 Mar;46(3 Suppl):281-90.
  104. Watt PJ, Hughes RB, et al. A holistic programmatic approach to natural hormone replacement. Fam Community Health. 2003;25(1):53-63.
  105. Al-Azzawi F, Bitzer J, Brandenburg U, Castelo-Branco C, Graziottin A, Kenemans P, Lachowsky M, Mimoun S, Nappi RE, Palacios S, Schwenkhagen A, Studd J, Wylie K, Zahradnik HP. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric. 2010 Apr;13(2):103-20.
  106. Braunstein GD. Androgen insufficiency in women: summary of critical issues. Fertil Steril. 2002;77(Suppl 4):S94–S99.
  107. Cameron DR , Braunstein GD. Androgen replacement therapy in women. Fertil Steril. 2004;82(2):273-289.
  108. Guillermo CJ, Manlove HA, Gray PB, Zava DT, Marrs CR. Female social and sexual interest across the menstrual cycle: the roles of pain, sleep and hormones. BMC Womens Health. 2010 May 27;10:19.
  109. Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. 2003;10(4):292–298.
  110. Zhou J, Ng S, et al. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J. 2000;14(12):1725–1730.
  111. Havlikova H, Hill M, Hampl R, et al. Sex- and age-related changes in epitestosterone in relation to pregnenolone sulfate and testosterone in normal subjects. J Clin Endocrinol Metab. 2002 May;87(5):2225-31.
  112. Mellon SH. Neurosteroid regulation of central nervous system development. Pharmacol Ther. 2007 Oct;116(1):107-24.
  113. Taylor M. Unconventional estrogens: estriol, biest, and triest. Clin Obstet Gynecol. 2001;44(4):864–879.
  114. Wright J. Stay Young and Sexy with Bio-Identical Hormone Replacement: The Science Explained. Published Dec. 16th 2009.
  115. Ling S, Komesaroff PA, Sudhir K. Cardiovascular physiology of androgens and androgen testosterone therapy in postmenopausal women. Endocr Metab Immune Disord Drug Targets. 2009 Mar;9(1):29-37.
  116. Stuckey BG. Female sexual function and dysfunction in the reproductive years: the influence of endogenous and exogenous sex hormones. J Sex Med. 2008 Oct;5(10):2282-90.
  117. Maia Jr H, Casoy J, Valente J. Testosterone replacement therapy in the climacteric: benefits beyond sexuality. Gynecol Endocrinol. 2009 Jan;25(1):12-20.
  118. Martin-Du Pan R. [Androgen deficiency in women: indication and risks of testosterone or DHEA treatment]. Rev Med Suisse. 2007 Mar 28;3(104):792-6.
  119. Davis SR, Moreau M, Kroll R, Bouchard C. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008 Nov 6;359(19):2005-17.
  120. Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr. 2009 May;89(5):1459-67.
  121. Aso T. Equol improves menopausal symptoms in Japanese women. J Nutr. 2010 Jul;140(7):1386S-9S.
  122. Cho YA, Kim J, Park KS, Lim SY, Shin A, Sung MK, Ro J. Effect of dietary soy intake on breast cancer risk according to menopause and hormone receptor status. Eur J Clin Nutr. 2010 Sep;64(9):924-32.
  123. Sarkar FH, Li Y. Soy isoflavones and cancer prevention. Cancer Invest. 2003;21(5):744–757.
  124. Zittermann A. [Phytoestrogens]. Zentralbl Gynakol. 2003;125(6):195–201.
  125. Adlercreutz H, Mousavi Y, Clark J, et al. Dietary phytoestrogens and cancer: in vitro and in vivo studies. J Steroid Biochem Mol Biol. 1992; 41(3–8):331–337.
  126. Baber R. Phytoestrogens and post reproductive health. Maturitas. 2010;66(4):344-9.
  127. Bawa S. The significance of soy protein and soy bioactive compounds in the prophylaxis and treatment of osteoporosis. J Osteoporos. 2010 Mar 8;2010:891058.
  128. Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J. 2008 Jun 3;7:17.
  129. Miyake A, Takeda T, Isobe A, et al. Repressive effect of the phytoestrogen genistein on estradiol-induced uterine leiomyoma cell proliferation. Gynecol Endocrinol. 2009 Jun;25(6):403-9.
  130. Vincent A, Fitzpatrick LA. Soy isoflavones: are they useful in menopause? Mayo Clin Proc. 2000;75(11):1174–1184.
  131. van der Schouw YT, Pijpe A, Lebrun CE, Bots ML, Peeters PH, van Staveren WA, Lamberts SW, Grobbee DE. Higher usual dietary intake of phytoestrogens is associated with lower aortic stiffness in postmenopausal women. Arterioscler Thromb Vasc Biol. 2002 Aug 1;22(8):1316-22.
  132. Okamura S, Sawada Y, et al. Pueraria mirifica phytoestrogens improve dyslipidemia in postmenopausal women probably by activating estrogen receptor subtypes. Tohoku J Exp Med. 2008;216(4): 341-351.
  133. De Kleijn MJ, van der Schouw YT, Wilson PW, et al. Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U.S. women: the Framingham study. J Nutr. 2002;132(2):276–282.
  134. Bairey Merz CN, Johnson BD, Braunstein GD, Pepine CJ, Reis SE, Paul-Labrador M, Hale G, Sharaf BL, Bittner V, Sopko G, Kelsey SF. Phytoestrogens and lipoproteins in women. J Clin Endocrinol Metab. 2006 Jun;91(6):2209-13.
  135. Ariyo AA, Villablanca AC. Estrogens and lipids. Can HRT designer estrogens, and phytoestrogens reduce cardiovascular risk markers after menopause? Postgrad Med. 2002;111(1):23–30.
  136. Teede HJ, Dalais FS, Kotsopoulos D, et al. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab. 2001 Jul;86(7):3053-60.
  137. Exner M, Hermann M, Hofbauer R, Kapiotis S, Quehenberger P, Speiser W, Held I, Gmeiner BM. Genistein prevents the glucose autoxidation mediated atherogenic modification of low density lipoprotein. Free Radic Res. 2001 Jan;34(1):101-12.
  138. Park D, Huang T, Frishman WH. Phytoestrogens as cardioprotective agents. Cardiol Rev. 2005;13(1):13–17.
  139. Ruiz-Larrea MB, Martin C, Martinez R, et al. Antioxidant activities of estrogens against aqueous and lipophilic radicals; differences between phenol and catechol estrogens. Chem Phys Lipids. 2000 Apr;105(2):179-88.
  140. Linford NJ, Dorsa DM, et al. 17beta-estradiol and the phytoestrogen genistein attenuate neuronal apoptosis induced by the endoplasmic reticulum calcium ATPase inhibitor thapsigargin. Steroids. 2002;67(13-14):1029-1040.
  141. Schreihofer DA, Redmond L. Soy phytoestrogens are neuroprotective against stroke-like injury in vitro. Neuroscience. 2009;158(2): 602-609.
  142. Donzelli A, Braida D, et al. Neuroprotective effects of genistein in mongolian gerbils: estrogen receptor-beta involvement. J Pharmacol Sci. 2010;114(2): 158-167.
  143. Ma Y, Sullivan JC, et al. Dietary genistein and equol (4', 7 isoflavandiol) reduce oxidative stress and protect rats against focal cerebral ischemia. Am J Physiol Regul Integr Comp Physiol. 2010;299(3): R871-877.
  144. Yu HL, Li L, et al. Neuroprotective effects of genistein and folic acid on apoptosis of rat cultured cortical neurons induced by beta-amyloid 31-35. Br J Nutr. 2009;102(5): 655-662.
  145. Hanna K, Wong J, Patterson C, et al. Phytoestrogen intake, excretion and markers of bone health in Australian women. Asia Pac J Clin Nutr. 2004;13(Suppl):S74.
  146. Taku K, Melby MK, Kurzer MS, et al. Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials. Bone.2010 Aug;47(2):413-23.
  147. Clifton-Bligh PB, Barber RJ, Fulcher GR, et al. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause. 2001 Jul-Aug;8(4):259-65.
  148. Kanno S, Hirano S, Kayama F. Effects of phytoestrogens and environmental estrogens on osteoblastic differentiation in MC3T3-E1 cells. Toxicology. 2004;196(1-2):137–145.
  149. Ma DF, Qin LQ, Wang PY, Katoh R. Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials. Clin Nutr. 2008 Feb;27(1):57-64. Epub 2007 Dec 11.
  150. Jia TL, Wang HZ, Xie LP, et al. Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production. Biochem Pharmacol. 2003;65(5):709–715.
  151. Rassi CM, Lieberherr M, Chaumaz G, et al. Down-regulation of osteoclast differentiation by daidzein via caspase 3. J Bone Miner Res. 2002;17(4):630–638.
  152. Yamaguchi M, Sugimoto E. Stimulatory effect of genistein and daidzein on protein synthesis in osteoblastic MC3T3-E1 cells: activation of aminoacyl-tRNA synthetase. Mol Cell Biochem. 2000;214(1–2):97–102.
  153. Zhang Y, Jin H, Xu Z, et al. Effects of genistein on bone mineral density and biomechanical properties and morphometric parameters in ovariectomized rats. Wei Sheng Yan Jiu. 2004;33(4):464–466.
  154. Atkinson C, Compston JE, Day NE, et al. The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr . 2004;79(2):326–333.
  155. Cotter A, Cashman KD. Genistein appears to prevent early postmenopausal bone loss as effectively as hormone replacement therapy. Nutr Rev. 2003;61(10):346–351.
  156. Vij U, Kumar A. Phyto-oestrogens and prostatic growth. Natl Med J India. 2004;17(1):22–26.
  157. Lu LJ, Anderson KE, Grady JJ, Nagamani M. Effects of an isoflavone-free soy diet on ovarian hormones in premenopausal women. J Clin Endocrinol Metab. 2001 Jul;86(7):3045-52.
  158. Lu LJ, Cree M, Josyula S, et al. Increased urinary excretion of 2-hydroxyestrone but not 16alpha-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Res. 2000;60(5):1299–1305.
  159. Lian Z, Niwa K, Tagami K, et al. Preventive effects of isoflavones, genistein and daidzein, on estradiol-17beta-related endometrial carcinogenesis in mice. Jpn J Cancer Res. 2001;92(7):726–734.
  160. Ko KP, Park SK, et al. Isoflavones from phytoestrogens and gastric cancer risk: a nested case-control study within the Korean Multicenter Cancer Cohort. Cancer Epidemiol Biomarkers Prev. 2010;19(5): 1292-1300.
  161. Albert A, Altabre C, Baro F, et al. Efficacy and safety of a phytoestrogen preparation derived from Glycine max (L.) Merr in climacteric symptomatology: a multicentric, open, prospective and non-randomized trial. Phytomedicine. 2002;9(2):85–92.
  162. Chiechi LM, Putignano G, Guerra V, et al. The effect of a soy rich diet on the vaginal epithelium in postmenopause: a randomized double blind trial. Maturitas. 2003. 45(4):241–246.
  163. Crisafulli A, Marini H, Bitto A, et al. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause. 2004;11(4):400–404.
  164. D'Anna R, Cannata ML, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study. Menopause. 2009;16(2): 301-306.
  165. Ferrari A. Soy extract phytoestrogens with high dose of isoflavones for menopausal symptoms. J Obstet Gynaecol Res. 2009;35(6): 1083-1090.
  166. Donnelly GF. Herbal efficacy: the case of black cohosh. Holist Nurs Pract. 2007 May-Jun;21(3):103.
  167. Oktem M, Eroglu D, Karahan HB, et al. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Adv Ther. 2007 Mar-Apr;24(2):448-61.
  168. Shams T, Setia MS, Hemmings R, et al. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. Altern Ther Health Med. 2010 Jan-Feb;16(1):36-44.
  169. Fang ZZ, Nian Y, Li W, Wu JJ, Ge GB, Dong PP, Zhang YY, Qiu MH, Liu L, Yang L. Cycloartane triterpenoids from Cimicifuga yunnanensis induce apoptosis of breast cancer cells (MCF7) via p53-dependent mitochondrial signaling pathway. Phytother Res. 2010 Jun 17. [Epub ahead of print].
  170. Al-Akoum M, Dodin S, Akoum A. Synergistic cytotoxic effects of tamoxifen and black cohosh on MCF-7 and MDA-MB-231 human breast cancer cells: an in vitro study. Can J Physiol Pharmacol. 2007 Nov;85(11):1153-9.
  171. Hostanska K, Nisslein T, Freudenstein J, et al. Evaluation of cell death caused by triterpene glycosides and phenolic substances from Cimicifuga racemosa extract in human MCF-7 breast cancer cells. Biol Pharm Bull. 2004;27(12):1970–1975.
  172. Nisslein T, Freudenstein J. Effects of an isopropanolic extract of Cimicifuga racemosa on urinary crosslinks and other parameters of bone quality in an ovariectomized rat model of osteoporosis. J Bone Miner Metab. 2003;21(6):370–376.
  173. Goh SY, Loh KC. Gynaecomastia and the herbal tonic "Dong Quai". Singapore Med J. 2001;42(3, pp. 115–116.
  174. Hardy ML. Herbs of special interest to women. J Am Pharm Assoc (Wash). 2000;40(2):234–242.
  175. Hirata JD, Swiersz LM, Zell B, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril. 1997;68(6):981–986.
  176. Burke BE, Olson RD, Cusack BJ. Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed Pharmacother. 2002;56(6):283–288.
  177. Hu C, Liu H, Du J, Mo B, Qi H, Wang X, Ye S, Li Z. Estrogenic activities of extracts of Chinese licorice (Glycyrrhiza uralensis) root in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):209-16.
  178. Armanini D, Fiore C, et al. History of the endocrine effects of licorice. Exp Clin Endocrinol Diabetes. 2002;110(6):257-261.
  179. Josephs RA, Guinn JS, Harper ML, Askari F. Liquorice consumption and salivary testosterone concentrations. Lancet. 2001 Nov 10;358(9293):1613-4.
  180. Ofir R, Tamir S, et al. Inhibition of serotonin re-uptake by licorice constituents. J Mol Neurosci. 2003;20(2):135-140.
  181. Somjen D. Knoll E, Vaya J, et al. Estrogen-like activity of licorice root constituents: glabridin and glabrene, in vascular tissues in vitro and in vivo. J Steroid Biochem Mol Biol. 2004;91(3):147–155.
  182. Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol. 2010 Dec 21. [Epub ahead of print].
  183. Chopin LB. Vitex agnus castus essential oil and menopausal balance: a research update. Ther Nurs Midwifery. 2003;9(3):157–160.
  184. Abbas S, Lineisen J, Slanger T, et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer—results of a large case-control study. Carcinogenesis. 2008 Jan;29(1):93-9.
  185. Ben-Shoshan M, Amir S, et al. 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 2007;6(4): 1433-1439.
  186. Lee HJ, Ji Y, et al. Activation of bone morphogenetic protein signaling by a Gemini vitamin D3 analogue is mediated by Ras/protein kinase C alpha. Cancer Res. 2007;67(24): 11840-11847.
  187. Jamshidi F, Zhang J, et al. Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling. Cell Cycle. 2008;7(7): 917-924.
  188. Crew KD, Gammon MD, et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila). 2009;2(6): 598-604.
  189. Lappe JM, Travers-Gustafson D, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85(6): 1586-1591.
  190. Lampe JW. Interindividual differences in response to plant-based diets: implications for cancer risk. Am J Clin Nutr. 2009 May;89(5):1553S-1557S. Epub 2009 Mar 18.
  191. Ambrosone CB, McCann SE, et al. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr. 2004;134(5): 1134-1138.
  192. Fowke JH, Longcope C, Hebert JR. Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):773-9.
  193. Muti P, Westerlind K, Wu T, et al. Urinary estrogen metabolites and prostate cancer: a case-control study in the United States. Cancer Causes Control. 2002 Dec;13(10):947-55.
  194. Muti P, Bradlow HL, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000;11(6): 635-640.
  195. Michnovicz JJ, Adlercreutz H, Bradlow HL. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst. 1997 May 21;89(10):718-23.
  196. Michnovicz JJ. Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol. Int J Obes Relat Metab Disord. 1998 Mar;22(3):227-9.
  197. Kall MA, Vang O, Clausen J. Effects of dietary broccoli on human drug metabolising activity. Cancer Lett. 1997 Mar 19;114(1-2):169-70.
  198. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-hydroxyestrone: the ‘good’ estrogen. J Endocrinol. 1996 Sep;150 SupplS259-65.
  199. Acharya A, Das I, Singh S, Saha T. Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis. Recent Pat Food Nutr Agric. 2010 Jun;2(2):166-77.
  200. Weng JR, Tsai CH, Kulp SK, Chen CS. Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett. 2008 Apr 18;262(2):153-63.
  201. Thompson LU, Chen JM, et al. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res. 2005;11(10): 3828-3835.
  202. Laidlaw M, Cockerline CA, Sepkovic DW. Effects of A Breast-Health Herbal Formula Supplement on Estrogen Metabolism in Pre- and Post-Menopausal Women not Taking Hormonal Contraceptives or Supplements: A Randomized Controlled Trial. Breast Cancer (Auckl). 2010 Dec 16;4:85-95.
  203. Buck K, Zaineddin AK, Vrieling A, Linseisen J, Chang-Claude J. Meta-analyses of lignans and enterolignans in relation to breast cancer risk. Am J Clin Nutr. 2010 Jul;92(1):141-53.
  204. Kansal S, Negi AK, et al. Evaluation of the role of oxidative stress in chemopreventive action of fish oil and celecoxib in the initiation phase of 7,12-dimethyl benz(alpha)anthracene-induced mammary carcinogenesis. Tumour Biol. 2010.
  205. Bougnoux P, Hajjaji N, et al. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer. 2009;101(12): 1978-1985.
  206. Sarotra P, Sharma G, Kansal S. Chemopreventive effect of different ratios of fish oil and corn oil in experimental colon carcinogenesis. Lipids. 2010 Sep;45(9):785-98.
  207. Mandal CC, Ghosh-Choudhury T, Yoneda T, Choudhury GG, Ghosh-Choudhury N. Fish oil prevents breast cancer cell metastasis to bone. Biochem Biophys Res Commun. 2010 Nov 26;402(4):602-7.
  208. Thangapazham RL, Passi N, et al. Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells. Cancer Biol Ther. 2007a;6(12): 1938-1943.
  209. Thangapazham RL, Singh AK, et al. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett. 2007b;245(1-2): 232-241.
  210. Leong H, Mathur PS, et al. Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea. Breast Cancer Res Treat. 2008;107(3): 359-369.
  211. Masuda M, Suzui M, et al. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol. 2002;2(6): 350-359.
  212. Farabegoli F, Barbi C, et al. (-)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detect Prev. 2007;31(6): 499-504.
  213. Hsuuw YD, Chan WH. Epigallocatechin gallate dose-dependently induces apoptosis or necrosis in human MCF-7 cells. Ann N Y Acad Sci. 2007;1095: 428-440.
  214. Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, Carr RE, Oikawa T, Lansky EP. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis. 2003;6(2):121-8.
  215. Sturgeon SR, Ronnenberg AG. Pomegranate and breast cancer: possible mechanisms of prevention. Nutr Rev. 2010 Feb;68(2):122-8.